BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less - 26 Fledgling Cameras for 2024: Ideal for New Photographic artists
- 3World's oldest known tortoise still very much alive despite rumor to the contrary
- 4Exclusive-Head of Pemex's production arm to step down in coming days, sources say
- 5Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
- Europe could get 42 more days of summer by the year 2100 due to climate change
- Which sandwich do you find totally delectable? !
- Crypto Investor’s Family Tied Up and Beaten by Armed Gangs in Their Home
- 2025 Was Another Exceptionally Hot Year
- 6 Popular Men's Aromas On the planet
- Step by step instructions to Safeguard Your Teeth During Sports Exercises
- 5 Bike Brands for Ordinary Use
- A new mom skipped a routine appointment. An infected cut led to a devastating diagnosis
- 10 High priority Contraptions for Tech Aficionados
